{"entity":{"type":"insider","cik":"0001456585","url":"/insider/0001456585","json_url":"/insider/0001456585.json","name":"Versant Side Fund III, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":8,"first":"2010-08-10","last":"2016-06-10","span_basis":"filed_date"},"name_variants":[{"name":"Versant Side Fund III, L.P.","source":"filing","n_filings":8,"first_seen":"2010-08-10","last_seen":"2016-06-10"}],"transactions":[{"id":2650541,"accession":"0001104659-16-126659","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-16-126659","line_url":"/filing/0001104659-16-126659","is_derivative":false,"issuer_cik":"0001181338","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001181338","owner_cik":null,"owner_name":"ATWOOD BRIAN G; ROBERTSON REBECCA B; COLELLA SAMUEL D; Versant Venture Capital III, L.P.; LINK WILLIAM J PHD; Versant Ventures III, LLC; JAFFE ROSS A MD; Versant Side Fund III, L.P.; MILDER DONALD B; Versant Development Fund III, L.P.","owner_display_name":"ATWOOD BRIAN G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":714285.0,"shares_display":"714,285","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":3511670.0,"shares_owned_after_display":"3,511,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-08","filed_date":"2016-06-10","scope":"insider","n_lines":2},{"id":3184598,"accession":"0001144204-16-104556","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-16-104556","line_url":"/filing/0001144204-16-104556","is_derivative":false,"issuer_cik":"0001181338","issuer_name":"PHASERX, INC.","issuer_ticker":"PZRX","issuer_name_source":null,"issuer_url":"/issuer/0001181338","owner_cik":null,"owner_name":"Versant Venture Capital III, L.P.; Versant Side Fund III, L.P.; LUBASH BARBARA N; Versant Ventures III, LLC; MILDER DONALD B; Praeger Robin L.; COLELLA SAMUEL D; JAFFE ROSS A MD; LINK WILLIAM J PHD; ATWOOD BRIAN G","owner_display_name":"Versant Venture Capital III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":258044.0,"shares_display":"258,044","price_per_share":0.01,"price_display":"0.01","price_state":"stated","total_value":2580.44,"total_display":"2,580.44","total_whole":"2,580","shares_owned_after":1334617.0,"shares_owned_after_display":"1,334,617","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-23","filed_date":"2016-05-24","scope":"insider","n_lines":4},{"id":3184584,"accession":"0001144204-16-104556","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-16-104556","line_url":"/filing/0001144204-16-104556","is_derivative":false,"issuer_cik":"0001181338","issuer_name":"PHASERX, INC.","issuer_ticker":"PZRX","issuer_name_source":null,"issuer_url":"/issuer/0001181338","owner_cik":null,"owner_name":"Versant Venture Capital III, L.P.; Versant Side Fund III, L.P.; LUBASH BARBARA N; Versant Ventures III, LLC; MILDER DONALD B; Praeger Robin L.; COLELLA SAMUEL D; JAFFE ROSS A MD; LINK WILLIAM J PHD; ATWOOD BRIAN G","owner_display_name":"Versant Venture Capital III, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600000.0,"shares_display":"600,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":1931094.0,"shares_owned_after_display":"1,931,094","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-23","filed_date":"2016-05-24","scope":"insider","n_lines":2},{"id":8344701,"accession":"0001209191-15-053412","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-053412","line_url":"/filing/0001209191-15-053412","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":null,"owner_name":"Versant Side Fund III, L.P.; Versant Venture Capital III, L.P.","owner_display_name":"Versant Side Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":320000.0,"shares_display":"320,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":7040000.0,"total_display":"7,040,000.00","total_whole":"7,040,000","shares_owned_after":2202377.0,"shares_owned_after_display":"2,202,377","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-15","filed_date":"2015-06-15","scope":"insider","n_lines":2},{"id":8793446,"accession":"0001209191-15-052367","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-052367","line_url":"/filing/0001209191-15-052367","is_derivative":false,"issuer_cik":"0001393434","issuer_name":"OCULAR THERAPEUTIX, INC","issuer_ticker":"OCUL","issuer_name_source":null,"issuer_url":"/issuer/0001393434","owner_cik":null,"owner_name":"Versant Venture Capital III, L.P.; Versant Side Fund III, L.P.","owner_display_name":"Versant Venture Capital III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":427000.0,"shares_display":"427,000","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":9394000.0,"total_display":"9,394,000.00","total_whole":"9,394,000","shares_owned_after":2520499.0,"shares_owned_after_display":"2,520,499","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-10","filed_date":"2015-06-11","scope":"insider","n_lines":2},{"id":8498984,"accession":"0001140361-15-019195","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001140361-15-019195","line_url":"/filing/0001140361-15-019195","is_derivative":false,"issuer_cik":"0001293818","issuer_name":"OPGEN INC","issuer_ticker":"OPGNOPGNW","issuer_name_source":null,"issuer_url":"/issuer/0001293818","owner_cik":null,"owner_name":"Versant Side Fund III, L.P.; Versant Ventures III, LLC; Versant Venture Capital III, L.P.","owner_display_name":"Versant Side Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":413332.0,"shares_display":"413,332","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":2479992.0,"total_display":"2,479,992.00","total_whole":"2,479,992","shares_owned_after":483072.0,"shares_owned_after_display":"483,072","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-05-08","filed_date":"2015-05-12","scope":"insider","n_lines":2},{"id":6571676,"accession":"0001123292-14-000785","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001123292-14-000785","line_url":"/filing/0001123292-14-000785#line-6","is_derivative":false,"issuer_cik":"0001437786","issuer_name":"Immune Design Corp.","issuer_ticker":"IMDZ","issuer_name_source":null,"issuer_url":"/issuer/0001437786","owner_cik":null,"owner_name":"Versant Venture Capital III, L.P.; Versant Side Fund III, L.P.","owner_display_name":"Versant Venture Capital III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":208334.0,"shares_display":"208,334","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":2500008.0,"total_display":"2,500,008.00","total_whole":"2,500,008","shares_owned_after":1974877.0,"shares_owned_after_display":"1,974,877","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-07-29","filed_date":"2014-07-31","scope":"insider"},{"id":6571672,"accession":"0001123292-14-000785","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001123292-14-000785","line_url":"/filing/0001123292-14-000785#line-5","is_derivative":false,"issuer_cik":"0001437786","issuer_name":"Immune Design Corp.","issuer_ticker":"IMDZ","issuer_name_source":null,"issuer_url":"/issuer/0001437786","owner_cik":null,"owner_name":"Versant Venture Capital III, L.P.; Versant Side Fund III, L.P.","owner_display_name":"Versant Venture Capital III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":233333.0,"shares_display":"233,333","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":2799996.0,"total_display":"2,799,996.00","total_whole":"2,799,996","shares_owned_after":2208210.0,"shares_owned_after_display":"2,208,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-07-29","filed_date":"2014-07-31","scope":"insider"},{"id":6375356,"accession":"0001209191-14-012247","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-14-012247","line_url":"/filing/0001209191-14-012247","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":null,"owner_name":"Versant Side Fund III, L.P.; Versant Development Fund III, L.P.; Versant Venture Capital III, L.P.","owner_display_name":"Versant Side Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":307692.0,"shares_display":"307,692","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":3999996.0,"total_display":"3,999,996.00","total_whole":"3,999,996","shares_owned_after":3205001.0,"shares_owned_after_display":"3,205,001","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-18","filed_date":"2014-02-20","scope":"insider","n_lines":2},{"id":7490101,"accession":"0001181431-10-041137","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-10-041137","line_url":"/filing/0001181431-10-041137#line-3","is_derivative":false,"issuer_cik":"0001356857","issuer_name":"Trius Therapeutics Inc","issuer_ticker":"TSRX","issuer_name_source":null,"issuer_url":"/issuer/0001356857","owner_cik":null,"owner_name":"Versant Side Fund III, L.P.; Versant Venture Capital III, L.P.","owner_display_name":"Versant Side Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":914529.0,"shares_display":"914,529","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":4572645.0,"total_display":"4,572,645.00","total_whole":"4,572,645","shares_owned_after":3235839.0,"shares_owned_after_display":"3,235,839","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-08-06","filed_date":"2010-08-10","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001419600","name":"Flexion Therapeutics Inc","url":"/issuer/0001419600","role":"Ten percent owner","n_filings":2,"first_seen":"2014-02-20","last_seen":"2016-06-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001429386","name":"PHASERX, INC.","url":"/issuer/0001429386","role":"Ten percent owner","n_filings":1,"first_seen":"2016-05-24","last_seen":"2016-05-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001393434","name":"OCULAR THERAPEUTIX, INC","url":"/issuer/0001393434","role":"Ten percent owner","n_filings":2,"first_seen":"2015-06-11","last_seen":"2015-06-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001293818","name":"OPGEN INC","url":"/issuer/0001293818","role":"Ten percent owner","n_filings":1,"first_seen":"2015-05-12","last_seen":"2015-05-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001437786","name":"Immune Design Corp.","url":"/issuer/0001437786","role":"Ten percent owner","n_filings":1,"first_seen":"2014-07-31","last_seen":"2014-07-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001356857","name":"Trius Therapeutics Inc","url":"/issuer/0001356857","role":"Ten percent owner","n_filings":1,"first_seen":"2010-08-10","last_seen":"2010-08-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001456585","retrieved_at":"2026-08-24T13:47:23+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}